Page last updated: 2024-12-11
thiomarinol
Description
thiomarinol: an antimicrobial antibiotic isolated from Alteromonas rava; a hybrid of 2 antibiotics, a pseudomonic acid analog and holothin; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
thiomarinol A : An organosulfur heterocyclic compound produced by a marine bacterium Alteromonas rava and has been shown to exhibit antibacterial activity against Gram-positive and Gram-negative bacteria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 5825095 |
MeSH ID | M0227162 |
Synonyms (8)
Synonym |
8-oxo-8-((5-oxo-4,5-dihydro[1,2]dithiolo[4,3-b]pyrrol-6-yl)amino)octyl 5,9-anhydro-2,3,8-trideoxy-8-(5-hydroxy-4-methyl-2-hexenyl)-3-methylnon-2-enonate |
[8-oxo-8-[(5-oxo-4h-dithiolo[4,3-b]pyrrol-6-yl)amino]octyl] (e)-4-[3,4-dihydroxy-5-[(e)-5-hydroxy-4-methyl-hex-2-enyl]tetrahydropyran-2-yl]-4-hydroxy-3-methyl-but-2-enoate |
[8-oxo-8-[(5-oxo-4h-dithiolo[4,3-b]pyrrol-6-yl)amino]octyl] (e)-4-[3,4-dihydroxy-5-[(e)-5-hydroxy-4-methylhex-2-enyl]oxan-2-yl]-4-hydroxy-3-methylbut-2-enoate |
thiomarinol a |
2-butenoic acid, 4-hydroxy-3-methyl-4-(tetrahydro-3,4-dihydroxy-5-(5-hydroxy-4-methyl-2-hexenyl)-2h-pyran-2-yl)-, 8-((4,5-dihydro-5-oxo-1,2-dithiolo(4,3-b)pyrrol-6-yl)amino)-8-oxooctyl ester |
thiomarinol |
146697-04-3 |
JIEMCPGFAXNCQW-BFHPBESDSA-N |
Research Excerpts
Overview
Thiomarinol is a naturally occurring double-headed antibiotic. It is highly potent against methicillin-resistant Staphylococcus aureus.
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (25.00) | 18.2507 |
2000's | 2 (16.67) | 29.6817 |
2010's | 6 (50.00) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (8.33%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (91.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |